EUCTR2009-012769-74-DE进行中（未招募）不适用
PHASE 1 SAFETY AND TOLERABILITY STUDY OF FIGITUMUMAB COMBINED WITH PEGVISOMANT IN PATIENTS WITH ADVANCED SOLID TUMORS
Pfizer Inc., 235 East 42nd Street, New York, NY 1100170 个研究点目标入组 46 人开始时间: 2009年8月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject eligibility should be reviewed and documented by an appropriately qualified member of the investigator’s study team before subjects are included in the study. Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
- •1. Patients must be =18 years of age. Exception: Patients =10 years of age with a diagnosis of advanced sarcoma will be included in the Sarcoma Expansion Cohort.
- •2. Histologic verification of malignancy at original diagnosis.
- •3. Patients =18 years of age with advanced solid tumors for which the combination of figitumumab and pegvisomant are reasonable treatment options.
- •4. Patient’s disease state may be appropriately treated with cytostatic therapy (ie, cytotoxic therapy is not required). The patient’s disease state should be considered by the investigator to be stable enough to allow the patient to complete 2 cycles (6 weeks) of study therapy.
- •5. Patients =10 years of age with a diagnosis of Ewing’s sarcoma family of tumors or other advanced sarcoma for which there is no available curative therapy or therapy proven to prolong survival with an acceptable quality of life will be included in the Sarcoma Expansion Cohort.
- •6. Total IGF-1 =100 ng/ml (13 nmol/L).
- •7. LDH <1.5 x ULN.
- •8. ECOG 0-1 (or Lansky =70% for patients <18 years of age).
- •9. Adequate recovery from major surgery prior to study treatment.
- •10. Patients must have fully recovered from the acute toxic effects of prior therapy toxicity = Grade 1 or deemed irreversible by investigator).
- •11. Adequate bone marrow function defined as:
- •? Platelet count =100,000/µL without transfusion support during the prior 7 days;
- •? Hemoglobin =9.0 gm/dL (RBC transfusions allowed);
- •? Peripheral absolute neutrophil count (ANC) =1000/µL without growth factor support during the 72 hours prior to enrollment.
- •12. Adequate renal function defined as creatinine =1.5xULN (upper limit of normal) and estimated creatinine clearance (eCrCl) =60 ml/min, calculated using the Cockcroft-Gault formula (refer to Appendix 5).
- •13. Adequate liver function defined as:
- •? Total bilirubin =1.5 x ULN (except patients with liver metastasis or Gilbert’s syndrome);
- •? Serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) =2.5 x ULN (=5 x ULN if liver function abnormalities are attributed to underlying malignancy);
- •14. Sexually active female patients must be either postmenopausal or, if of childbearing age, must be surgically sterile or must agree to use effective contraception during the period of therapy and up to 5 months after the last dose of figitumumab. Acceptable contraception includes, but is not limited to: oral hormone therapy, partner vasectomy, or double barrier contraception (which is defined as a male condom plus spermicide in combination with either a female condom, or diaphragm, or cervical cap or intrauterine device). The following forms are not acceptable: withdrawal method, rhythm method, spermicide, barrier sponge with or without spermicide. Within these limits, the specific form of contraception employed is left to the discretion of the subject, principal Investigator, and/or primary care physician. Sexually active male patients must be sterile or must agree to use effective contraception during the period of therapy and up to 5 months after the last dose of figitumumab.
- •15. All patients must sign and date a written voluntary informed consent document indicating that the subject (or a legally acce
排除标准
- •Unless compelling reason(s) to be agreed upon and documented by the investigator and sponsor, subjects presenting with any of the following will not be included in the study:
- •1. Concurrent treatment with any anti-tumor agents.
- •2. Participation in other studies within 28 days before the current study begins and/or during study.
- •3. Concurrent therapy with a somatostatin analogue.
- •4. CNS tumors or brain metastases.
- •5. Pregnant or breastfeeding females.
- •6. Significant active cardiac disease including but not limited to:
- •? Left ventricular ejection fraction <50%;
- •? Uncontrolled hypertension (disastolic BP >90 mmHg); During the Sarcoma expansion cohort, the blood pressure for patients <18 years of age should be within normal limits for age. Refer to the following reference: ? Any ventricular arrhythmia; ? Mitral valve regurgitation > trivial as determined by Doppler Echocardiogram. ? Any history of the following risk factors: Unstable angina, symptomatic congestive heart failure, myocardial infarction, cerebrovascular accident. ? Transient ischemic attack within the previous 6 months. ? Pulmonary embolism or other significant thromboembolic event within the previous 3 months. ? Requirement of ionotropic support, including digoxin. ? Use of pacemaker or implanted defibrillator.
- •7. Subjects receiving or are likely to require corticosteroids at doses higher than physiologic replacement (ie, Prednisone equivalent 5 mg/day) or other immunosuppressive therapy during study participation.
- •8. Active infection, including hepatitis B or C, or receiving antiretroviral therapy for HIV disease.
- •9. Glycosylated hemoglobin (HgbA1c) =5.7%.
- •10. History of diabetes mellitus.
- •11. Concurrent treatment with medications indicated for the treatment of diabetes mellitus.
- •12. History of allergic reaction to IgGs.
- •13. History of hypersensitivity to any pegvisomant component, including latex. The stopper on the vial of pegvisomant contains latex.
- •14. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for study entry.
- •15. Subjects who have been admitted to an institution by virtue of an order issued by either the judicial or administrative authorities.
研究者
相似试验
进行中（未招募）
不适用
PHASE 1 SAFETY AND TOLERABILITY STUDY OF FIGITUMUMAB COMBINED WITH PEGVISOMANT IN PATIENTS WITH ADVANCED SOLID TUMORSAdvanced Solid TumorsMedDRA version: 9.1Level: LLTClassification code 10049280Term: Solid tumourEUCTR2009-012769-74-FIPfizer Inc., 235 East 42nd Street, New York, NY 11001746
撤回
1 期
Safety and tolerability of the Traditional Chinese Medicine Formulation GOPAC in patients with advanced malignancyAdvanced malignancy (palliative)Cancer - Other cancer typesACTRN12609000652279Sydney South West Area Health Service70
已完成
不适用
A phase I study of the safety, tolerability, and antitumor activity of escalating doses of combretastatin A4 phosphate given in combination with bevacizumab to subjects with advanced solid tumorsAdvanced solid tumoursSolid tumoursCancerISRCTN96787846OXiGENE, Inc. (USA)12
招募中
1 期
utetium-177-anti-Programmed Cell Death-Ligand 1 single domain antibodies (177Lu-anti-PD-L1 sdAb) in metastatic non-small cell lung cancerMetastatic Non-small Cell Lung CancerCancer - Lung - Non small cellACTRN12623000959673Radiopharm Theranostics Ltd23
已完成
不适用
Phase 1b study of safety and tolerability in patients treated with stereotactic radiotherapy combined with durvalumab and tremelimumab in stage 4 NSCLCNon-small cell lung cancer (NSCLC)10038666NL-OMON44296niversitair Medisch Centrum Groningen25